Gilead’s statement on access to remdesivir outside of clinical trials:   Gilead is working to rapidly assess the safety and efficacy of remdesivir as a potential treatment for COVID-19 through multiple ongoing clinical trials. Enrollment in clinical trials is the primary way to access remdesivir to generate critical data that inform the appropriate use of this investigational medicine.   We recognize that there are severely ill patients who are unable to enroll in clinical trials and for who...